![]() | |
Clinical data | |
---|---|
Other names | YZJ-1139; YZJ1139 |
Routes of administration | Oral [1] |
Drug class | Orexin receptor antagonist [1] [2] [3] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H25FN4O2 |
Molar mass | 432.499 g·mol−1 |
3D model (JSmol) | |
| |
|
Fazamorexant (INN ; developmental code name YZJ-1139) is an orexin receptor antagonist which is under development for the treatment of insomnia. [1] [4] [2] [3] It is taken by mouth. [1]
The drug acts as a dual orexin receptor antagonist (DORA), or as an antagonist of both the orexin OX1 and OX2 receptors. [2] [3]
Fazamorexant is under development by Jiangsu Yangtze River Pharmaceutical Group and/or Shanghai Haiyan Pharmaceutical Technology in China. [1] [4] [2] As of September 2022, it is in phase 3 clinical trials for insomnia. [1] [4] [3] Relatively little public information is available on fazamorexant. [2] This was such that it had to be excluded from a 2020 literature review of orexin receptor antagonists for insomnia. [2]